Advanced searches left 3/3

Vitamin K - DOAJ

Summarized by Plex Scholar
Last Updated: 09 August 2022

* If you want to update the article please login/register

The role of vitamin K during pregnancy – a literature review

Newborns have a low natural vitamin K deficiency because they do not get the appropriate amount in the antenatal period, which is attributed to the slower movement of this vitamin in the placenta. Vitamin K, especially vitamin K, can cause an increase in infant mortality in newborns, which are closely related to hypovitaminosis K. The use of drugs that affect vitamin K metabolism by pregnant women can raise the risk of various disorders in newborns, particularly in fetal development.

Source link: https://doi.org/10.37897/RMJ.2021.4.7


Neglected vitamin K deficiency causing coagulation dysfunction in an older patient with pneumonia: a case report

Abstract Background The development of coagulation disorders in older people can be both risky and fatal, particularly those with multiple medical disorders. Case description We present a case where a 71-year-old male suffering from a bacterial infection with severe coagulation disorder without bleeding signs. Vitamin K deficiency was thought to be the cause of coagulation disorders during long-term antibiotic therapy, particularly cephalosporins, inadequate diet, and abnormal liver function. Conclusions: Overall, timely vitamin K supplementation with antimicrobials that affect vitamin K metabolism, whether you're multimorbid, frail, or nutritionally impaired, and hospitalized due to an illness that necessitates hospitalization due to altered gut flora, which may exacerbate existing nutritional deficiencies.

Source link: https://doi.org/10.1186/s12877-022-03327-6


Non-vitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients with heart failure and preserved, mildly reduced, and reduced ejection fraction: A systemic review and meta-analysis

We are looking for the ability and safety of non-vitamin K antagonist oral anticoagulants and warfarin in AF patients with HF and preserved, marginally reduced, and reduced ejection fraction in January 2022, according to Methods and results. Patients with AF and HF have reduced the risk of SSE, all-cause mortality, major bleeding, and intracranial hemorrhage by comparing NOACs with warfarin. NOACs reduced the chances of SSE in the HFrEF group and major bleeding in HFmrEF and HFpEF groups, according to further studies based on the HF subtypes. Conclusion:In the HFrEF study, there were no differences between SSE in HFmrEF and HFpEF groups, as well as major bleeding, but NOACs had greater or equal safety than warfarin, but the stroke prevention superiority of NOACs over warfarin varies in different HF subtypes.

Source link: https://doi.org/10.3389/fcvm.2022.949726


Effectiveness and safety of non-vitamin K direct oral anticoagulants in atrial fibrillation patients with bioprosthetic valve.

Background Non-vitamin K direct oral anticoagulant is a safe and effective method of preventing embolic events in non-valvular atrial fibrillation patients. However, the benefits and safety of DOAC in AF patients with bioprosthetic heart valves are largely unknown. Methods We retrospectively identified patients with AF and BPHV using the diagnostic code and medical device manufacturer and surgery information from the Korean National Health Insurance Service website between 2013 and 2018. The mean CHA2DS2-VASc score was 4. 7 points higher than that of u00b11. 4 percent, which was 4. 7 percent. The Department of Defense (DoAC) was non-inferior to warfarin for preventing ischemic stroke and systemic embolism, extensive bleeding, and all-cause death. DOAC was also similar to warfarin, as for the net clinical result. DoAC was at least as effective and safe as warfarin for the prevention of systemic embolic incidents in this national Korean AF population with a BPHV. These findings reveal that DOAC may be a safe alternative to warfarin in AF patients with BPHV.

Source link: https://doi.org/10.1371/journal.pone.0268113


Prothrombin induced by vitamin K absence or antagonist-II (PIVKA-II) predicts complete responses of transarterial chemoembolization for hepatocellular carcinoma

The standard approach for intermediate stage HCC is transarterial chemoembolization, but there are no such predictors. We investigated the use of PIVKA-II as a predictor of TACE response. Methods: This prospective analysis included consecutive patients with HCC experiencing TACE in Taiwan. Serum PIVKA-III levels were determined before and serially after TACE, before and sequentially after TACE. Results: We included 46 patients with HCC, as well as Barcelona Clinic Liver Cancer stages A, B, or C. Patients with infiltrative HCC or HCC exceeding the up-to-7 requirements had significantly higher baseline PIVKA-III levels than those without. PIVKA-III predicted CR to TACE in patients BCLC A and B, poor baseline PIVKA-II, whereas high PIVKA-II predicted uncontrolable tumor formation. Moreover, serial PIVKA-III levels post TACE were much lower in patients with a CR to TACE than those without, as well as those without. Conclusion: A lower baseline PIVKA-III level helps to anticipate a CR of TACE in patients with HCC.

Source link: https://doi.org/10.1016/j.jfma.2022.01.005


Safety and efficacy of low-dose non-vitamin K antagonist oral anticoagulants versus warfarin after left atrial appendage closure with the Watchman device

Patients with atrial fibrillation are expected to have anticoagulant therapy within 45 days after Watchman device implantation for stroke prevention in patients with atrial fibrillation. Within 45 days after the introduction of a Watchman device in a Chinese population, the present research sought to compare the safety and effectiveness of using different anticoagulants. Patients with a successful Watchman device implantation from October 2014 to June 2020 were enrolled in this study. According to the type of postprocedural anticoagulants, most patients were released anticoagulants within 45 days after the procedure, and patients were divided into three groups according to the type of postprocedural anticoagulants. In the warfarin group, major bleeding was more prevalent, while minor bleeding was similar among the groups. Conclusion: The safety and efficacy of low-dose dabigatran and rivaroxaban were comparable to those of warfarin within 45 days after the introduction of a Watchman device in a Chinese population.

Source link: https://doi.org/10.1016/j.jfma.2021.10.015

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions